Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) has been assigned an average rating of "Hold" from the seven brokerages that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $1.75.

Separately, StockNews.com started coverage on Akebia Therapeutics in a research note on Tuesday. They issued a "hold" rating for the company.

Institutional Trading of Akebia Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas increased its stake in shares of Akebia Therapeutics by 37.2% in the 4th quarter. Teacher Retirement System of Texas now owns 32,286 shares of the biopharmaceutical company's stock worth $73,000 after acquiring an additional 8,759 shares during the last quarter. Virtus ETF Advisers LLC increased its stake in shares of Akebia Therapeutics by 18.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 69,015 shares of the biopharmaceutical company's stock worth $156,000 after acquiring an additional 10,772 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of Akebia Therapeutics in the 4th quarter worth $30,000. Rice Hall James & Associates LLC increased its stake in shares of Akebia Therapeutics by 5.6% in the 1st quarter. Rice Hall James & Associates LLC now owns 513,292 shares of the biopharmaceutical company's stock worth $368,000 after acquiring an additional 27,072 shares during the last quarter. Finally, Swiss National Bank increased its stake in shares of Akebia Therapeutics by 7.8% in the 1st quarter. Swiss National Bank now owns 393,085 shares of the biopharmaceutical company's stock worth $282,000 after acquiring an additional 28,300 shares during the last quarter. 31.56% of the stock is owned by institutional investors and hedge funds.

Akebia Therapeutics Trading Down 3.1 %

Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.54. Akebia Therapeutics had a negative return on equity of 197.12% and a negative net margin of 55.04%. The firm had revenue of $126.76 million during the quarter, compared to the consensus estimate of $49.10 million. During the same period in the prior year, the company earned ($0.51) EPS. On average, equities research analysts forecast that Akebia Therapeutics will post -0.44 earnings per share for the current fiscal year.

About Akebia Therapeutics

(Get Rating)

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.

Featured Stories

• Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
• The Worst May be Over for Target, But is the Stock Safe to Buy?
• Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
• Two Fun Stocks The Insiders Are Buying
• Novavax Remains a Risk-On Stock in a Risk-Off Market
• 3 Defensive Stocks With 60-Year Dividend Hike Streaks

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.